Elucid's core product, PlaqueIQ, is an AI-powered computed tomography angiography (CTA) analysis software that objectively quantifies and characterizes arterial plaque and is FDA-cleared. The software simulates histology and is validated against tens of thousands of tissue annotations by pathologists. Elucid is pursuing an additional indication for non-invasive fractional flow reserve measurement (FFRCT) uniquely derived from its PlaqueIQ technology. The plaque analysis software is commercially available in the U.S., UK, EU, and South Korea. The company has been ramping commercial efforts, expanding clinical research and development, and has significantly bolstered its leadership team. Financially, Elucid announced an $80 million Series C and has raised $121 million in total funding since inception. Elucid builds interpretable, validated AI software that non-invasively quantifies atherosclerotic plaque characteristics compared to histopathology, including lipid rich necrotic core. Its machine-learning algorithms characterize tissue types in the artery wall and power applications that derive FFRct, estimate risk of heart attack/stroke, and produce expression-prediction outputs to inform therapeutic selection. The platform enables physicians to diagnose causes of chest pain and detect early-stage heart disease not visible with alternative methods. The software is FDA-cleared and CE-marked and is commercially available in the U.S., Europe, and South Korea. Led by CEO Blake Richards, the company intends to use new funding to accelerate growth and further development efforts. No revenue or user metrics were reported in the article. Elucid develops interpretable, validated AI software (ElucidVivo) to help physicians detect cardiovascular disease and optimize treatment decisions. ElucidVivo is the first FDA-cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics versus histopathology, including lipid-rich necrotic core, and is commercially available in the U.S. and Europe. The company has published studies on deriving fractional flow reserve (FFRct) from vasodilative vessel-wall capacity and on estimating coding and non-coding RNA transcripts (“Virtual Transcriptomics”). Management says the technology aims to reduce invasive procedures, improve diagnostic power, and enable precision medicine for cardiac and neurovascular patients. Recent hires include Jason Bottiglieri as Chief Commercial Officer and Murali Ayyapillai as Vice President of Engineering to support commercialization and product development. The company plans to continue advancing and commercializing its platform to improve outcomes and reduce healthcare costs.

Total raised

$115M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2023